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Vitamin D Supplementation and Systemic Lupus Erythematosus 
Pamela Rangen, PA-S, M.Ed., RRT-NPS, AE-C 
Abstract 
Introduction 
 Systemic lupus erythematosus is an autoimmune inflammatory 
disease with diverse clinical manifestations which affects 
several different organ systems. 
 Vitamin D deficiency is widespread and has been associated 
with many chronic diseases, including autoimmune disorders. 
 Vitamin D and its analogs may be related to the prevention of 
autoimmune diseases, but they could also be used to treat such 
diseases. 
 Vitamin D can also be considered as a potential anti-
inflammatory agent and immunosuppressant. 
 
 
Research Question 
Literature Review 
Applicability to Clinical Practice 
Acknowledgements  
Discussion 
 Patients with systemic lupus erythematosus (SLE) are prone to 
hypovitaminosis D because of their photosensitivity. 
 Vitamin D has beneficial effects not only on bone metabolism 
but also on the function of the immune system. 
 Vitamin D levels depend on many variables, including sun 
exposure, age, ethnicity, body mass index, use of medications 
and supplements. 
 Patients with SLE avoid the sun because of photosensitive 
rashes and potential for disease flare, so adequate oral 
supplementation is critical. 
 In addition, to the traditional known metabolic activities, 
vitamin D has been shown to modulate the immune system, and 
its deficiency has been linked to the development of several 
autoimmune disorders including SLE. 
 The purpose of this review was to determine if vitamin D has an 
immunosuppressive effect and if it can suppress autoimmunity. 
 The findings indicated that repletion of vitamin D has benefits 
beyond bone health for patients with certain autoimmune 
disorders, such as SLE. 
 
 In patients with systemic lupus erythematosus, is vitamin D 
supplementation an effective adjunctive therapy to standard 
medical therapy at increasing the probability of remission of 
systemic lupus erythematosus? 
 A set of criteria by the American College of Rheumatology 
(ACR) can be used in the diagnosis of SLE.   
 The ACR criteria includes: malar rash, discoid rash, 
photosensitivity, oral ulcers, arthritis (joint pain and swelling of 
two or more joints in which the bones around the joints do not 
become destroyed), serositis (pleuritic pain or pericarditis), 
kidney disorders (persistent protein or cellular casts in the 
urine), neurologic disorder (seizures or psychosis), blood 
disorder (anemia, leukopenia, lymphopenia or 
thrombocytopenia), immunologic disorder (anti-DNA or anti-
SM or positive antiphospholipid antibodies, and abnormal 
antinuclear antibody (ANA). 
 Four of the eleven criteria must be met in order to diagnose 
SLE. 
 Medications to treat SLE manifestations include:  biologic 
disease-modifying antirheumatic drugs, nonbiological disease-
modifying antirheumatic drugs, nonsteroidal anti-inflammatory 
drugs, corticosteroids, and anti-malarial drugs.   
 Vitamin D deficiency is defined as a serum concentration of 25-
hydroxyvitamin D [25 (OH) D] < 20 ng/ml.  
 Vitamin D insufficiency is defined as a serum concentration of 
25-hydroxyvitamin D [25 (OH) D] 20-29 ng/ml. 
 Vitamin D Optimal level is defined as a serum concentration of 
25-hydroxyvitamin D [25 (OH) D] 30-80 ng/ml. 
 The link between vitamin D and SLE was first described in 
1995.  The discovery of vitamin D receptor expression by cells 
of the immune system has spurred  research on the 
immunomodulatory properties of vitamin D.  Both the innate 
and adaptive immune systems have a wide array of cells such as 
macrophages, dendritic cells, T cells, and B cells which express 
vitamin D receptors that may respond to the biologically active 
form of  vitamin D (1,25-dihydroxyvitamin D). 
  
  
 The reported prevalence of systemic lupus erythematosus in the 
population is 20 to 150 cases per 100,000.  In women, 
prevalence rates vary from 164 (white) to 406 (African 
American) per 100,000.   
 Due to improved detection of mild disease, the incidence nearly 
tripled in the last 40 years.  Estimated incidence rates are 1 to 25 
per 100,000 in North American, South America, Europe and 
Asia. 
 Vitamin D supplementation is considered to be safe, 
inexpensive, and widely available agent that may be effective as 
a disease-suppressing intervention for patients with SLE alone 
with their current medical regimen. 
 One could propose the reduction or discontinuance of current 
standard medical intervention by supplementation of vitamin D.  
The application of cost-effectiveness to patients also plays a 
clinical role. 
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Statement of the Problem 
 The prevalence and incidence of autoimmune diseases, such as 
systemic lupus erythematosus is on the rise.  
 Researchers have identified 80-100 different autoimmune 
diseases and suspect at least 40 additional diseases of having an 
autoimmune basis. 
 Further research is needed into the immune system and vitamin 
D deficiency, one process involved in development of 
autoimmune disease. 
 This research can further explore the potential outcome of 
vitamin D supplementation and suppression of autoimmunity. 
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 Vitamin D has also been shown to facilitate progression of 
existing autoimmune disease.  In a study by Zold et al., 161 
patients with an early undifferentiated connective tissue disease 
were followed for a mean of over two years.  Most patients did 
not progress and remained in an undifferentiated state.  Thirty-
five (21%) patients went on to develop a defined rheumatologic 
diagnosis including rheumatologic diagnosis including 
rheumatoid arthritis, SLE, mixed connective tissue disease, and 
sjogren’s disease while 126 did not progress.  Baseline 
characteristics of the two groups were similar.  Importantly, the 
mean vitamin D level was significantly lower in the group that 
progressed to a definitive disease. 
 Indication and dosing to achieve and maintain adequate levels 
of 25 (OH) D depends on the initial serum level and individual 
risk factors of each patient, such as obesity. Malabsorption 
disease, concomitant medications, and limited sun exposure. 
 On average, 100 IU/day of vitamin D intake is needed to 
increase 1 ng/ml of serum 25 (OH) D, which takes about 3 
months to become stable once supplementation is started. 
